Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04342806|
Recruitment Status : Completed
First Posted : April 13, 2020
Last Update Posted : October 27, 2022
|Condition or disease|
|Health Care Worker (HCW) COVID-19|
The HERO Registry provides a resource for collecting information on Healthcare Workers (HCWs) currently working in the United States, and their family members and communities. The overall goal of the Registry is to create and engage a community of HCWs and their families and communities who may be eligible for participation in future research studies, including those of COVID-19 prophylaxis and treatment. The HERO registry will create a repository of adults interested in COVID-19 research that can be eligible for future research studies. The main objectives of the study are 1) create a virtual community of adult HCWs in the United States, and their families and communities, 2) Identify adults interested in engaging in upcoming research studies, including those related to COVID-19, and 3) Create a dataset of health related measurements, risk factors, and outcomes for future analysis. The population of interest is adult healthcare workers in the United States, and their families and communities.
All analysis of the HERO Registry will be exploratory in nature. Analysis may include descriptive statistics of the cohort, statistical associations between variables of interest, and predictive modeling for health outcomes and behaviors. Analyses may be conducted on all participants in the HERO Registry or may be conducted on subpopulations defined based on clinical, demographic or other factors.
There is no direct benefit to the participants for their participation in this study, but the information obtained will be used in scientific research and may be helpful to the participant or others in the future. Participants may experience indirect benefits such as learning about their own health, access to health data, and opportunities to participate in future research.
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||51466 participants|
|Target Follow-Up Duration:||2 Years|
|Official Title:||Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study|
|Actual Study Start Date :||April 10, 2020|
|Actual Primary Completion Date :||September 30, 2022|
|Actual Study Completion Date :||September 30, 2022|
HCWs currently working in the US, and their families and communities
The HERO Registry will include HCWs currently working across the United States, and their families and communities. For the purposes of this study, a "healthcare worker" is defined as an individual who currently works in a setting where individuals receive healthcare. (Note: individuals do not have to work directly with patients, but may have any role within a setting where individuals receive healthcare, such as housekeeping, food service, etc.)
- Number and percent of participants who enroll in the HERO Registry Study by geographic region, age, COVID-19 risk factors, and past COVID-19 diagnosis [ Time Frame: Up to 79 years ]
- Distribution of COVID-19 risk factors by participant characteristics [ Time Frame: Up to 79 years ]
- Proportion of participants undergoing changes in health status (e.g. new diagnosis of COVID-19, ER visits, hospitalization) [ Time Frame: Up to 79 years ]
- Proportion of all participants enrolled in the HERO Registry who participate in an ancillary research study [ Time Frame: Up to 79 years ]
- Proportion of participants who continue to supply information about their health to the HERO Registry at various time points after their enrollment [ Time Frame: Up to 79 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04342806
|United States, North Carolina|
|Duke Clinical Research Institute|
|Durham, North Carolina, United States, 27701|
|Principal Investigator:||Emily O'Brien, PhD||Duke University|